17,159 Shares in TransMedics Group, Inc. $TMDX Acquired by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company bought a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 17,159 shares of the company’s stock, valued at approximately $1,140,000.

A number of other institutional investors and hedge funds have also made changes to their positions in TMDX. Algert Global LLC increased its holdings in shares of TransMedics Group by 124.6% in the 2nd quarter. Algert Global LLC now owns 57,154 shares of the company’s stock valued at $3,796,000 after acquiring an additional 31,710 shares during the period. Biondo Investment Advisors LLC bought a new stake in TransMedics Group during the second quarter valued at about $2,933,000. Emerald Investment Advisers LLC purchased a new position in TransMedics Group in the second quarter valued at about $2,023,000. EP Wealth Advisors LLC purchased a new position in TransMedics Group in the second quarter valued at about $1,023,000. Finally, Keebeck Wealth Management bought a new position in TransMedics Group in the second quarter worth about $387,000. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at TransMedics Group

In other news, Director Thomas J. Gunderson sold 9,624 shares of the firm’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $75.06, for a total value of $722,377.44. Following the completion of the transaction, the director directly owned 16,642 shares in the company, valued at $1,249,148.52. This trade represents a 36.64% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 6.90% of the company’s stock.

TransMedics Group Price Performance

Shares of TMDX opened at $89.98 on Friday. The company has a debt-to-equity ratio of 1.62, a current ratio of 6.62 and a quick ratio of 6.07. The company’s fifty day moving average price is $80.14 and its 200-day moving average price is $92.21. TransMedics Group, Inc. has a 1-year low of $60.10 and a 1-year high of $156.00. The firm has a market capitalization of $3.11 billion, a PE ratio of 23.13 and a beta of 1.90.

TransMedics Group (NASDAQ:TMDX) last issued its earnings results on Tuesday, August 4th. The company reported $0.44 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.06). TransMedics Group had a return on equity of 15.88% and a net margin of 22.69%.The firm had revenue of $189.95 million during the quarter, compared to analysts’ expectations of $184.00 million. During the same quarter last year, the business earned $0.92 EPS. The business’s revenue was up 20.7% on a year-over-year basis. On average, equities research analysts predict that TransMedics Group, Inc. will post 1.46 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. Zacks Research cut shares of TransMedics Group from a “hold” rating to a “strong sell” rating in a report on Monday, July 6th. Weiss Ratings upgraded shares of TransMedics Group from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday. Stifel Nicolaus increased their target price on shares of TransMedics Group from $75.00 to $80.00 and gave the company a “hold” rating in a research report on Thursday, June 18th. TD Cowen restated a “buy” rating and issued a $120.00 target price on shares of TransMedics Group in a research note on Wednesday, July 1st. Finally, UBS Group cut their price target on shares of TransMedics Group from $80.00 to $77.00 and set a “neutral” rating on the stock in a report on Wednesday, August 5th. Six investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, TransMedics Group presently has a consensus rating of “Hold” and a consensus target price of $124.18.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.